41 results
8-K
EX-99.1
ARAV
Aravive Inc
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising; the Company's ability to expand development into additional
8-K
EX-99.1
ARAV
Aravive Inc
11 Aug 22
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
7:15am
on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional indications
8-K
EX-99.1
ARAV
Aravive Inc
5 Jul 22
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7:05am
to enroll the expected number of patients, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising
8-K
EX-99.1
ARAV
Aravive Inc
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional
8-K
EX-99.1
ARAV
Aravive Inc
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
to enroll the expected number of patients, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising
8-K
EX-99.1
bfh6g67jdg530ep
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
EX-99.1
fjz0q6qs3
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
EX-99.1
p2nn8yildjdkyhq2
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
twmw79 zvdc0m
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
ungqkgqh2vfz8tgz7l
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
8-K
EX-99.1
p7v8bdo
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
czt5udzmhjv3kay
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
50mgqm4q04j7vyn2decj
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
74rh7f og7ushuqkma
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
t4k7v30
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
fv520p9gl 3p5
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
uocvqqt2
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
xq3m2r o2r1yca
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
kcojks25k
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am